Loading...
Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours
Barriuso, Jorge Custodio, A Afonso, R Alonso, V Astudillo, A Capdevila, J Garcia-Carbonero, R Grande, E Jimenez-Fonseca, P Marazuela, M
Barriuso, Jorge
Custodio, A
Afonso, R
Alonso, V
Astudillo, A
Capdevila, J
Garcia-Carbonero, R
Grande, E
Jimenez-Fonseca, P
Marazuela, M
Citations
Altmetric:
Abstract
Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms regarding their molecular biology, clinical behaviour, prognosis and response to therapy. Several attempts to establish robust predictive biomarkers have failed. Neither tissue markers nor blood borne ones have proven to be successful yet. Circulating tumour cells (CTCs) as "liquid biopsies" could provide prognostic information at the time a therapeutic decision needs to be made and could be an attractive tool for tumour monitoring throughout the treatment period. However, "liquid biopsies" are far from becoming the standard biomarker in NETs. Promising results have been presented over the last few years using a novel biomarker candidate, a multianalyte algorithm analysis PCR-based test (NETest). New technologies will open the field to different ways of approaching the biomarker conundrum in NETs. However, the complications derived from being a heterogeneous group of malignancies will remain with us forever. In summary, there is an unmet need to incorporate new biomarker candidates into clinical research trials to obtain a robust prospective validation under the most demanding scenario.
Description
Date
2018
Publisher
Collections
Keywords
Type
Article
Citation
Barriuso J, Custodio A, Afonso R, Alonso V, Astudillo A, Capdevila J, et al. Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. Cancer Treat Rev. 2018 Nov;70:209-22.